In multiple sclerosis (MS), the presence of autoantibodies once thought to be unique to MS have since being subcategorised into rarer demyelinating diseases of the central nervous system (CNS), such as autoantibodies against myelin oligodendrocyte glycoprotein (MOG) which distinguishes MOG-antibody associated disease. Here, MOG is linked to demyelinating disease.